NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Anbio Biotechnology

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026

$3.27+0.14 (+4.47%)

Close on Oct 19, 2026

Community

Notes and questions about Anbio Biotechnology from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Anbio Biotechnology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NNNN.

Revenue growth5.6% · median -1.4%

Gross margin87.2% · median 37.5%

Operating margin66.7% · median -80.7%

Net margin74.1% · median -76.9%

Advertisement
300 × 250